Arrestin recruitment and signaling by G protein-coupled receptor heteromers

• Published in: Neuropharmacology 2019-07, Vol.152, p.15-21
• Main Authors: Mores, Kendall L., Cassell, Robert J., van Rijn, Richard M.
• Format: Article
• Language: English
• Subjects: Allosteric Regulation - physiology; Arrestins - metabolism; Beta-arrestin; beta-Arrestins; Biased signaling; G protein-coupled receptor; Heteromerization; Heteroreceptor complex; Protein Multimerization; Receptors, G-Protein-Coupled - metabolism; Signal Transduction; Trafficking
• ISSN: 0028-3908; 1873-7064
• DOI: 10.1016/j.neuropharm.2018.11.010

G protein-coupled receptors (GPCR) have a long history of being considered a prime target for drug development to treat a plethora of diseases and disorders. In fact in 1827, the first approved therapeutic in the United States was morphine, a drug that targets a GPCR, namely the mu opioid receptor. However, with the rise in biologics over the last two decades, the market share of small molecules targeting GPCRs has declined. Still, two phenomena concerning GPCR pharmacology, specifically heteromerization and biased signaling, have bolstered new interests in this particular class of drug targets. Heteromerization, the process by which two distinct GPCRs come together to form a unique signaling complex, has been demonstrated between many different GPCRs and has spurred efforts to discover heteromer selective drugs. Additionally, the discovery of biased signaling, a concept by which a GPCR can transduce intracellular signaling by favoring a specific pathway (e.g. G-protein) over another pathway (e.g. arrestin), has led to the development of signal-biased drugs with potentially fewer side effects. Our goal for this review is to highlight studies that have investigated the interplay of these two phenomena by providing an overview of the current literature describing instances where GPCR heteromers have distinct arrestin recruitment profiles when compared to the individual GPCRs, with a focus on those GPCRs expressed in the central nervous system. This article is part of the Special Issue entitled ‘Receptor heteromers and their allosteric receptor-receptor interactions’. [Display omitted] •GPCR heteromers exhibit unique pharmacology in relation to arrestin recruitment.•Compared to the individual GPCRs some heteromers have decreased arrestin recruitment.•Compared to the individual GPCRs some heteromers have increased arrestin recruitment.•Heteromer-mediated arrestin recruitment can alter MAPK signaling.•Heteromer-mediated arrestin signaling may play a role in analgesia and locomotion.